Salute e Benessere
ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach
"We are delighted to bring ILM-Blue to the Chinese market, where it will provide retina surgeons with a proven, high-quality staining solution to enhance visualization," says Jessie Jiang Bo , General Manager of DORC in China . "This approval reinforces our dedication to expanding access to innovative ophthalmic solutions that help surgeons to improve patient outcomes."
ILM-Blue is used to clearly stain and easily distinguish the inner limiting membrane (ILM) from underlying retinal layers during vitreoretinal surgery. This facilitates membrane removal and reduces the risk of retinal damage . Since its launch in 2010, ILM-Blue from DORC has been used in more than 900,000 procedures worldwide , consistently supporting vitreoretinal surgeons to improve patient outcomes and setting new standards in posterior segment surgery. With this latest approval, ILM-Blue becomes the first DORC posterior dye product available in China , bringing its trusted solution and proven benefits to healthcare professionals and patients in the region.
To date, ILM-Blue remains the only ILM staining solution approved by the FDA. It is marketed under the brand name TissueBlue in the U.S. and is listed as the #1 preferred ILM stain among U.S. retina surgeons .
Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
Email: investors.med@zeiss.com
Frank Smith
Head of Global Communications Ophthalmology
Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Email: press.med@zeiss.com
www.zeiss.com/newsroom
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).
The Group's head office is located in Jena, Germany , and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA , Japan , Spain and France . The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China , strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
For more information visit our website at
D.O.R.C. is one of the world's leading suppliers of equipment, instruments and liquids for ophthalmic surgery. For over 40 years, D.O.R.C. has grown into a successful international business, shaping its product portfolio through close collaboration with leading top surgeons. The company improves eye surgery globally and maximizes surgeon control by providing innovative quality approaches for eye disorders. Its products are exported to more than 80 countries worldwide. The company is headquartered in Zuidland, the Netherlands , and has more than 800 employees. In April 2024 , D.O.R.C. was acquired by Carl Zeiss Meditec AG.
Photo - https://mma.prnewswire.com/media/2650992/ILM_BLUE.jpg
Logo - https://mma.prnewswire.com/media/546786/ZEISS_v1_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ilm-blue-from-dorc-receives-nmpa-approval-in-china-expanding-global-reach-302412650.html